Mia
Mia Akerfeldt, Waverly AU
Patent application number | Description | Published |
---|---|---|
20130171158 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 - A method of treating or preventing an abnormality of glucose metabolism in a subject, the method comprising administering an antagonist of Inhibitor of Differentiation 1 (Id1) to the subject. | 07-04-2013 |
Mia Anastsopoulos, Nunawading AU
Patent application number | Description | Published |
---|---|---|
20090044313 | Sock - A sock having a toe portion and a heel and ankle portion joined by a generally tubular body portion, wherein the body portion is formed in a composite fabric of an elastane and one or more other components such that the elastane density varies in the body portion in a manner effective to allow the sock to fit a wider range of standard foot sizes than for a similar sock having uniform elastane density in the body portion. | 02-19-2009 |
Mia Bjar, Krakeroy NO
Patent application number | Description | Published |
---|---|---|
20130206172 | OIL REMOVAL METHOD AND APPARATUS - A device for removing spilled oil, oily substances or other liquids from a surface has a main body with a pair of handles towards its upper end and a cleaning head at the lower end. The cleaning head is fitted with rotary brushes and also contains a motor and drive gear. At the upper end of the main body, a flexible pipe is connected to a hollow passage formed by and extending through the main body via a short flexible pipe to the cleaning head. In the opposite direction, the flexible pipe extends to remote air pressure, vacuum and sorbent material sources. The device has three main modes of operation which are used in sequence to supply absorbent material (e.g., chipped bark) to the contaminated ground; then the absorbent material is massaged into the surface of the ground; and finally the absorbent material together with the liquid is removed. | 08-15-2013 |
Mia Dvora, Raleigh, NC US
Patent application number | Description | Published |
---|---|---|
20130101548 | Whey Protein Isolate Hydrogels and Their Uses - A biodegradable hydrogel has been made based on high concentrations of whey protein isolate (WP1). WP1 gels of different compositions were fabricated by thermally inducing gelation of high-concentration suspensions of protein, and characterized for compressive strength and modulus, hydration swelling and drying properties, mechanical behavior change due to polysaccharide additives, and intrinsic pore network structure. The gels were shown to be compatible with bone cells and could be used as bone tissue scaffolds. In addition, WP1 fibers were produced by electrospinning. Several additives could be incorporated into the WPI gels, including structural additives, growth factors, amino acids, etc. The WP1 hydrogels can be made with glycerol to increase flexibility and stability. The hydrogels could be used for tissue regeneration, food protection, controlled-release applications (including drug encapsulation, dietary supplement release, attractant release in lures, nutrient release to plants (fertilizers), column packing for compound separation, and membrane development. | 04-25-2013 |
Mia Engström, Turku FI
Patent application number | Description | Published |
---|---|---|
20100004339 | Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists - The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein R1, R2, R3, A, B, D, Q, k and n are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes SSTR1 and/or SSTR4 and can be used for the treatment or diagnosis of diseases or conditions wherein an interaction with SSTR1 and/or SSTR4 is indicated to be useful. | 01-07-2010 |
Mia Engström, Espoo FI
Patent application number | Description | Published |
---|---|---|
20100048549 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 - The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein A, D, E, J, Q1 R1, R2, R3, p and j are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes sst | 02-25-2010 |
Mia Engström, Turku FI
Patent application number | Description | Published |
---|---|---|
20100004339 | Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists - The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein R1, R2, R3, A, B, D, Q, k and n are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes SSTR1 and/or SSTR4 and can be used for the treatment or diagnosis of diseases or conditions wherein an interaction with SSTR1 and/or SSTR4 is indicated to be useful. | 01-07-2010 |
Mia Engström, Espoo FI
Patent application number | Description | Published |
---|---|---|
20100048549 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 - The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein A, D, E, J, Q1 R1, R2, R3, p and j are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes sst | 02-25-2010 |
Mia Herou, Bankeryd SE
Patent application number | Description | Published |
---|---|---|
20120102755 | Electrical Two-Way Rotary Trimmer - An electrical trimmer ( | 05-03-2012 |
Mia Hunter, Hackensack, NJ US
Patent application number | Description | Published |
---|---|---|
20150033443 | Absorbent Headband Device for Bathing - A moisture absorbent headband device is provided comprising a highly absorbent inner layer and a fabric outer shell layer. The absorbent inner layer is adapted to absorb moisture while the outer shell layer comprises a water permeable material that forms a continuous, closed loop structure having an enclosed interior volume supporting the absorbent inner layer therein. The outer shell layer is an elastic material adapted to be worn around the head of a wearer, generally a young child, whereby the inner layer absorbs water and soap in contact therewith to prevent the same from entering the wearer's face and eyes. The inner layer is a substantially rectangular cuboid shape having a thickness, length, and height, whereby the length thereof is adapted to extend sufficiently around the closed loop of the outer shell layer such that the inner layer rests above the ears and across the wearer's forehead when donned. | 02-05-2015 |
Mia Jullig, Waiheke Island NZ
Patent application number | Description | Published |
---|---|---|
20160095826 | METHODS OF DIAGNOSIS AND TREATMENT - A method for diagnosing a cardiac ischemic event and a kit for detecting biomarkers used in the method. Also provided is a method for treating a PPAR-related disorder by administering a pharmaceutical composition containing one or more long chain fatty acids. | 04-07-2016 |
Mia Levite, Savyon IL
Patent application number | Description | Published |
---|---|---|
20080311657 | Killing Human Lymphoma and Leukemia Cancer Cells and Tcr-Activated Normal Human Cells By Dopamine D1r Agonists - The dopamine D1/D5 receptor is highly over-expressed in various types of human and animal leukemia, lymphoma and activated T-cells. The dopamine D1 receptor is also expressed in dramatically elevated or even moderate levels in other types of cancer cells. Selective dopamine D1 receptor agonists, such as fenoldopam mesylate, rapidly, potently and selectively kill such human and animal T-cells expressing the dopamine D1 receptor. Thus, selective dopamine D1/5 receptor agonists may be used to treat lymphoma, leukemia and other cancers of the immune system, and T-cell mediated autoimmune diseases and other diseases caused by over-activated inflammatory T-cells (such as chronic inflammation), or graft versus host diseases (GVHD) or graft rejection, or by any other cell types expressing the dopamine D1 receptor, by killing the disease-causing cells. The selective dopamine D1/5 receptor agonists can be used for these purposes either in vivo or in vitro, such as to purge a given cell population from undesired leukemia, lymphoma or activated T-cells prior to further use. | 12-18-2008 |
20090022739 | MODULATING THE KV1.1 VOLTAGE-GATED POTASSIUM CHANNEL IN T-CELLS FOR REGULATING THE SYNTHESIS AND SECRETION OF TUMOR NECROSIS FACTOR ALPHA (tnf-ALPHA) AND TREATING HUMAN DISEASE OR INJURIES MEDIATED BY DETRIMENTALLY HIGH OR LOW LEVELS OF TNF-ALPHA - Blocking the voltage-gated potassium channel Kv1.1 of T-cells causes the robust and exclusive production of TNF-α, and thus can be used for eradication of cancer, improved eradication of infectious organisms, increased permeability of blood vessels and the blood brain barriers to given molecules and cells, and improved neuronal features, regeneration function and development. Blocking the voltage-gated potassium channel Kv1.1 of T-cells causes the robust and exclusive production of TNF-α. Similarly, unblocking of a blocked Kv1.1 channel or opening of a Kv1.1 channel will prevent the T-cells from producing and secreting excess amounts of TNF-α, thus being useful in the treatment of conditions such as rheumatoid arthritis and for treating neurological diseases associated with defected functioning and/or pathological block of the Kv1.1 channel, among them PNH associated with Kv1 Abs; Encephalitis associated with Kv1 Abs; and Episodic-ataxia type 1 (EA-1), in all of which the T-cell blocked Kv1.1 channel may secrete excess TNFa and thereby contribute to the pathology. Blocking of the Kv1.1 channel may be achieved in vivo or ex vivo by contact with a selective Kv1.1 channel blocking molecule such as Dendrotoxin-K or a selective monoclonal antibody against the Kv1.1 channel. Preventing the Kv1.1. block would be achieved by Kv1.1 openers, or by molecules that would prevent the closure of the Kv1.1 channel. | 01-22-2009 |
20090221069 | METHOD FOR AUGMENTING THE ABILITY OF T-CELLS AND OTHER CELLS FOR FIGHTING DISEASE AND INVADE DISEASED ORGANS, FOR ELEVATING CD3 ZETA AND TNF-ALPHA EXPRESSION IN T-CELLS, AND MIXING T-CELL BOOSTING AND KIT PARTICULARLY USEFUL IN SUCH METHOD - A method and device for augmenting the ability of T-cells, NK cells and other body cells, of a patient for fighting disease and invading diseased tissue, and for elevating the level of CD3 zeta expression in T cells for better functioning of these T-cells and their augmented capability to eliminate cancer and infectious organisms, by exposing, for a predetermined exposure period, the first substance of T-cell or other cells to a second substance having a T-cell-boosting capability, such as, but not limited to CD3 zeta elevating capability, increased CXCR4, CD147, 67-kDa laminin receptor and/or any other key receptor in T-cells capability, increased tissue invasion capability, TNFa elevating capability, to augment the ability of the separated cells to fight the disease; and following the predetermined exposure period, reintroducing the first substance of T-cells back into the blood of the subject. The first substance is exposed to the second substance by mixing the two substances in a mixing device providing hermetically-sealed conditions effective to maintain sterility in both substances during the mixing and to maintain tissue culture conditions required for the cells viability thereof and for the required exposure period. | 09-03-2009 |
20110104287 | FENOLDOPAM FORMULATIONS AND PRO-DRUG DERIVATIVES - Formulations of fenoldopam are disclosed for repeated administration or continued slow release administration, over prolonged periods of time or targeted slow and regulated delivery. The formulations include those formulations that increase the bioavailability of fenoldopam after oral intake, particularly lipid based nano dispersions and pronanodispersions and surfactant rich formulations. This may be accomplished by entrapment in nanoparticles or liposomal formulations or conjugation to a polymer or small molecule via a soft bond. | 05-05-2011 |
Mia Pirskanen, Kuopio FI
Patent application number | Description | Published |
---|---|---|
20090155230 | Novel genes and markers in essential arterial hypertension - The present invention relates to previously unknown disease associations between various genes, loci and biomarkers and essential hypertension. The detection of these biomarkers provides novel in vitro methods and test kits which can be used as an aid when making risk assessment, molecular diagnosis or prognosis of HT or a HT related condition. The disclosed methods and test kits do not require interaction with the body of a subject during the biomarker detection. Instead the methods and test kits are for in vitro use (e.g. in a clinical laboratory) and typically biological samples for the biomarker analyses using a method or a test kit of this invention have been collected earlier in a different place. In addition the biomarkers provide methods and systems for identifying novel agents for preventing, treating and/or reducing risk of HT or a HT related condition. The HT associated genes can be used to develop novel therapies for prevention and/or treatment of essential hypertension. | 06-18-2009 |
20110111404 | Novel genes and markers in type 2 diabetes and obesity - Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed. | 05-12-2011 |
Mia Pirskannen, Kuopio FI
Patent application number | Description | Published |
---|---|---|
20110111405 | Novel genes and markers in type 2 diabetes and obesity - Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed. | 05-12-2011 |